TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19153339

Group type: EXPERIMENTAL
Intervention: Topical tretinoin, 0.1%, applied twice daily to the face and ears
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Vehicle control cream, applied twice daily to the face and ears
Number of subjects: 1131
Study: 17005814

Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 400/200/600
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 300/200/600
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 300/100
Number of subjects: 71

Group type: COMPARATOR
Intervention: RIF 600 alone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 300/200/600 and ATV/RTV/RIF 400/200/600
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ATV with RIF
Number of subjects: 71
Study: 12770652

Group type: EXPERIMENTAL
Intervention: 10 mg of nifedipine intranasally delivered
Number of subjects: 989

Group type: COMPARATOR
Intervention: Control group (surgery postponed for BP control)
Number of subjects: 989
Study: 11139975

Group type: EXPERIMENTAL
Intervention: Tuned biphasic waveforms (based on an RC model with a time constant of 3.5 ms)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard biphasic waveforms (phase 1 set to 65% tilt and phase 2 = phase 1)
Number of subjects: 91
Study: 9493669

Group type: EXPERIMENTAL
Intervention: Nasal Proportional Assist Ventilation (PAV)
Number of subjects: 42
Study: 8886294

Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride 0.3 mg/kg intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2552868

Group type: EXPERIMENTAL
Intervention: Dexamethasone isonicotinate (four puffs bid for seven days, ie, 0.5 mg bid for seven days; last four puffs 30 minutes before TDI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexamethasone isonicotinate
Number of subjects: 6
Study: 4596620

Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31739245

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 μg·kg-1·min-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 12
Study: 29261655

Group type: EXPERIMENTAL
Intervention: Routine cell salvage use
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Current standard of care without routine salvage use
Number of subjects: 3028
Study: 26255060

Group type: EXPERIMENTAL
Intervention: Air current directed at the face
Number of subjects: 10
Study: 23408763

Group type: EXPERIMENTAL
Intervention: Weight loss (WL) group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Baseline RBP4 levels
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Total testosterone levels
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SHBG levels
Number of subjects: 48

Group type: COMPARATOR
Intervention: Weight regain (WR) group
Number of subjects: 48
Study: 21705157

Group type: COMPARATOR
Intervention: Saline injection (3 mL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Autologous blood injection (3 mL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (3 mL)
Number of subjects: 34
Study: 19882878

Group type: EXPERIMENTAL
Intervention: Bronchial asthma (BA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (DM1)
Number of subjects: 0
Study: 16799446

Group type: EXPERIMENTAL
Intervention: New model of school dental screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional model of school dental screening
Number of subjects: 0
Study: 15245891

Group type: EXPERIMENTAL
Intervention: 99mTc labelled microballoons (MB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfloating microspheres (NF) (control)
Number of subjects: 0
Study: 10942162

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) at 5 pmol/min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) at 10 pmol/min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) at 20 pmol/min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 19
Study: 9311397

Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood for 18 hours
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (received allogeneic red cells if hemoglobin < 5 mmol/L)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Autotransfusion group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood
Number of subjects: 120
Study: 8456428

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of hirulog (0.6 mg kg-1 h-1 for 2 h)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of hirulog
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of hirulog
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous hirulog
Number of subjects: 54
Study: 2994698

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20
Study: 30297909

Group type: EXPERIMENTAL
Intervention: Combined ipilimumab with nivolumab
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 23
Study: 26924770

Group type: EXPERIMENTAL
Intervention: Targeted therapies for metastatic renal cell carcinoma
Number of subjects: 5549

Group type: EXPERIMENTAL
Intervention: Increase NLR at Week 6 by 25-50%
Number of subjects: 5549

Group type: EXPERIMENTAL
Intervention: Increase NLR at Week 6 by > 75%
Number of subjects: 5549

Group type: EXPERIMENTAL
Intervention: Decrease NLR at Week 6 by 25-50%
Number of subjects: 5549

Group type: COMPARATOR
Intervention: No change in NLR (decrease < 25% to increase < 25%)
Number of subjects: 5549
Study: 24809264

Group type: EXPERIMENTAL
Intervention: High PEEP (11-30 cmH2O)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal PEEP (3-10 cmH2O)
Number of subjects: 120
Study: 22340541

Group type: EXPERIMENTAL
Intervention: Fish oil (0.2 g/kg) and soybean oil (1.0 g/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Soybean oil (1.2 g/kg)
Number of subjects: 57
Study: 20590759

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Internal endoscopic biliary drainage (internal EBD)
Number of subjects: 59
Study: 18820784

Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 30
Study: 16279145

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 64
Study: 12445220

Group type: EXPERIMENTAL
Intervention: Prototype brush head N2.3 for the Philips Jordan Sensiflex 2000 PTB
Number of subjects: 137
Study: 10348424

Group type: EXPERIMENTAL
Intervention: Treadmill walking in patients with arteriosclerosis obliterans
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treadmill walking in normal subjects (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Walking with arrested blood circulation to a lower limb
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Walking speed and duration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heart rate during walking and recovery
Number of subjects: 23
Study: 8745020

Group type: EXPERIMENTAL
Intervention: Prednisone and trimethoprim-sulfamethoxazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1674231

Group type: EXPERIMENTAL
Intervention: 75 mg of roxatidine acetate at night
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study: 6223699

Group type: EXPERIMENTAL
Intervention: Etodolac (mean daily dose: 319 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin (mean daily dose: 4,701 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31601180

Group type: EXPERIMENTAL
Intervention: Point-of-care gastric sonography
Number of subjects: 102
Study: 28791977

Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS)
Number of subjects: 26
Study: 27629128

Group type: EXPERIMENTAL
Intervention: Adjuvant RT following radical hysterectomy (Group 1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adjuvant RT following type 1 hysterectomy (Group 2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Primary curative RT (Group 3)
Number of subjects: 55
Study: 24329972

Group type: EXPERIMENTAL
Intervention: Extended cognitive behavioral therapy
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard cessation treatment without extended cognitive behavioral therapy
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Extended nicotine replacement therapy
Number of subjects: 402
Study: 22040514

Group type: EXPERIMENTAL
Intervention: Authority Acceptance scale from the Teacher Observation of Classroom Adaptation‐Revised (AA‐TOCA‐R)
Number of subjects: 8820

Group type: EXPERIMENTAL
Intervention: Item scaling of the AA‐TOCA‐R
Number of subjects: 8820
Study: 19688862

Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV)
Number of subjects: 22
Study: 17403440

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC)
Number of subjects: 1716
Study: 15270789

Group type: EXPERIMENTAL
Intervention: Pioglitazone (initially 30 mg QD, titrated to 45 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Glibenclamide (initially 1.75 mg QD, titrated to 10.5 mg)
Number of subjects: 200
Study: 11172962

Group type: EXPERIMENTAL
Intervention: Group A: 10 x 3 Gy (total dose, 30 Gy) in 2 series (5 x 3Gy) separated by 8 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Group B: 7 x 3 Gy (total dose, 21 Gy) in 1 series within 2 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 129
Study: 9543065

Group type: COMPARATOR
Intervention: GM-CSF alone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: IL-3 followed by GM-CSF
Number of subjects: 115
Study: 8083702

Group type: EXPERIMENTAL
Intervention: Investigational therapies in adjuvant therapy RCTs (14 of 90 RCTs)
Number of subjects: 77488

Group type: EXPERIMENTAL
Intervention: Investigational therapies in advanced-disease therapy RCTs (3 of 141 RCTs)
Number of subjects: 77488

Group type: COMPARATOR
Intervention: Dose-intensity with blood-product support trials
Number of subjects: 77488

Group type: COMPARATOR
Intervention: Locally advanced disease trials
Number of subjects: 77488
Study: 3056259

Group type: EXPERIMENTAL
Intervention: Norfloxacin for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norfloxacin for 12 weeks followed by placebo for 12 weeks
Number of subjects: 0
Study: 29124324

Group type: EXPERIMENTAL
Intervention: Mental Fatigue (MF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 11
Study: 28082211

Group type: EXPERIMENTAL
Intervention: Glycerin suppositories every 8 hours during phototherapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: No glycerin suppositories (sham group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Glycerin suppositories
Number of subjects: 79
Study: 26311445

Group type: EXPERIMENTAL
Intervention: Hamstring autograft
Number of subjects: 99

Group type: COMPARATOR
Intervention: Tibialis posterior allograft
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups (autograft and allograft)
Number of subjects: 99
Study: 24263274

Group type: EXPERIMENTAL
Intervention: High-fidelity patient simulator (HPS) training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 19
Study: 21297190

Group type: EXPERIMENTAL
Intervention: Higher-intensity aerobic (ATH; 80% VO₂peak)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic (ATM; 65% VO₂peak)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower-intensity resistance (RTL; 50% VO₂peak)
Number of subjects: 30
Study: 18768369

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day for 5 years)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 227
Study: 16361368

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (resveratrol and genistein) and selective estrogen receptor-alpha agonist (PPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPT and genistein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytoestrogens and PPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: 17beta‐E2
Number of subjects: 0
Study: 15273454

Group type: EXPERIMENTAL
Intervention: Backup pacing (AAI at 30 beats per minute)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Atrioventricular interval (AVI) of 30 ms (DDD30)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Optimized AVI (DDDop)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quality-of-life (QOL) testing
Number of subjects: 32
Study: 11456430

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 750
Study: 9226602

Group type: EXPERIMENTAL
Intervention: Sexually explicit video before sleep
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dysphoric arousal video before sleep
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lecture (neutral) video before sleep
Number of subjects: 12
Study: 8289616

Group type: EXPERIMENTAL
Intervention: Stair-climbing (STAIR)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Run training (RUN)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (STAIR and RUN)
Number of subjects: 23
Study: 3542775

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31778310

Group type: EXPERIMENTAL
Intervention: Gravity-induced blood flow restriction (BFR) aerobic exercise (AE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Work rate‐matched non‐BFR aerobic exercise (AE)
Number of subjects: 13
Study: 30067289

Group type: EXPERIMENTAL
Intervention: Telemetric gas-sensing capsule (1.25-40 g inulin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Telemetric gas-sensing capsule (20 or 40 g glucose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Breath test (standard protocols)
Number of subjects: 12
Study: 27998215

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (3 telephone-based sessions over 1 month)
Number of subjects: 164
Study: 25948727

Group type: EXPERIMENTAL
Intervention: IV bolus injection of 2.0 mg/kg cyclosporine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 23418886

Group type: EXPERIMENTAL
Intervention: Web-based guided self-help course (6 weekly lessons with weekly support from a coach)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Care-as-usual (no additional treatment)
Number of subjects: 200
Study: 20635617

Group type: EXPERIMENTAL
Intervention: Collaborative testing
Number of subjects: 2

Group type: COMPARATOR
Intervention: Individual testing
Number of subjects: 2
Study: 18254985

Group type: EXPERIMENTAL
Intervention: Carrot juice (330 ml per day for 2 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml per day for 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Carrot juice and Tomato juice
Number of subjects: 22
Study: 16175532

Group type: EXPERIMENTAL
Intervention: Transverse incision (n = 32)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vertical incision (n = 37)
Number of subjects: 69
Study: 12843036

Group type: EXPERIMENTAL
Intervention: ETB-positive S. aureus strains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of staphylococcal plasmid encoding multiple antibiotic resistance traits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staphylococcal nasal carriage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonal type of S. aureus
Number of subjects: 0
Study: 10374223

Group type: EXPERIMENTAL
Intervention: Initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy without initial gestagen treatment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Initial gestagen treatment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Negative progesterone challenge test
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Positive progesterone challenge test
Number of subjects: 86
Study: 8708877

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (6-week group treatment providing nutritional education and management strategies)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 9
Study: 2065411

Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms.kg-1 infused over 30 sec (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alfentanil 25 micrograms.kg-1 infused (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alfentanil 12.5 micrograms.kg-1 infused (Group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No alfentanil administered (Group 4)
Number of subjects: 80
Study: 6558011

Group type: EXPERIMENTAL
Intervention: Staff support program (9 weeks, insight-oriented approach with structured exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-program levels of stress and job satisfaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-program levels of stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Job satisfaction post-program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Turnover among nursing staff on hospice unit
Number of subjects: 0
Study: 31982887

Group type: EXPERIMENTAL
Intervention: Combination of monochromatic 308-nm excimer light (MEL) and topical calcipotriol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Topical calcipotriol alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of MEL and topical calcipotriol
Number of subjects: 18
Study: 30786757

Group type: EXPERIMENTAL
Intervention: Participants with repaired cleft palate
Number of subjects: 76

Group type: COMPARATOR
Intervention: Participants without cleft palate
Number of subjects: 76
Study: 29960800

Group type: EXPERIMENTAL
Intervention: MenACWY-TT and Tdap co-administered at Month 0 (Co-ad group)
Number of subjects: 660

Group type: COMPARATOR
Intervention: MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: MenACWY-TT and Tdap co-administered
Number of subjects: 660
Study: 27630949

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Arimedadi oil mouthwash
Number of subjects: 45
Study: 25212745

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Montelukast (5/5 stratum)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Placebo (5/5 stratum)
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Montelukast (5/x+x/x stratum)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Placebo (5/x+x/x stratum)
Number of subjects: 1358
Study: 22633362

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC) 40 mg/40 ml, three instillations per week for 2 weeks (group 2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravesical mitomycin C (MMC) 40 mg/40 ml, one instillation per week for 6 weeks (group 1)
Number of subjects: 54
Study: 20211945

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 691

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 691
Study: 17164834

Group type: EXPERIMENTAL
Intervention: In-center daily HD (1.5-2.75 h, 6 days/week)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Home nocturnal HD (≥ 6 h, 6 nights/week)
Number of subjects: 250

Group type: COMPARATOR
Intervention: In-center daily HD
Number of subjects: 250

Group type: COMPARATOR
Intervention: Home nocturnal HD
Number of subjects: 250
Study: 15886432

Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 0
Study: 12050241

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a dose of 0.005-0.010 mg/kg.d for 6 months
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 10760843

Group type: EXPERIMENTAL
Intervention: Oral solution (5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral tablet formulation (5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous infusion (5 mg)
Number of subjects: 14
Study: 8672197

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group therapy
Number of subjects: 42
Study: 2147698

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment 0.05%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 343032

Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: 800 mg of ibuprofen
Number of subjects: 510

Group type: COMPARATOR
Intervention: 650 mg of aspirin
Number of subjects: 510

Group type: COMPARATOR
Intervention: 65 mg of propoxyphene HCl
Number of subjects: 510

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 510
Study: 31941553

Group type: EXPERIMENTAL
Intervention: Wearing habitual correction (cc)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not wearing habitual correction (sc)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Wearing habitual correction (cc) for IED detection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not wearing habitual correction (sc) for IED detection
Number of subjects: 30